Paediatric rhabdomyosarcoma survival extended with maintenance chemotherapy

Dr Bisogno presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from a randomised phase III clinical trial of 6 months maintenance chemotherapy for children with the rare disease rhabdomyosarcoma.

For those receiving the low dose chemotherapy following initial treatments, 5 year overall survival improved from 73.7% to 86.5%, which is the first improvement in this indication for more than 30 years.

For more detail, watch Dr Bisogno speak with ecancer about the trial here, or read our news coverage here.
https://ecancer.org/news/14117.php

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php